Agilent Advanced Therapeutics delivers integrated development and manufacturing solutions for synthetic small molecules, including complex chemistries, intermediates, and HPAPIs.
Our capabilities span route design, process optimization, analytical development, scale-up, and cGMP production supported by advanced containment and harmonized, ICH-aligned quality systems. With proven regulatory experience, robust tech transfer, and end-to-end analytical and stability testing, we help reduce risk, improve reliability, and advance programs efficiently from early development through commercial supply.
End-to-end chemical development—Route scouting, optimization, impurity control, and scalable process design.
Large-scale commercial manufacturing—Flexible production from 1 kg to over 200 MT annually across multi-purpose suites.
Flow chemistry expertise—Enhanced safety, yield, and throughput for highly reactive or exothermic transformations.
Specialty chemistries—Lipid synthesis, PEGylation, linker chemistries for ADCs, and controlled substance manufacturing.
Advanced purification—High-capacity chromatographic purification, including 80 cm RP columns for commercial-scale polishing.
Find helpful answers to common questions as you evaluate and advance your program
What scales of synthetic small molecule manufacturing do you offer?
We support production from gram-scale development batches through commercial-scale manufacturing exceeding 200 MT annually, with multipurpose suites capable of handling complex chemistries and controlled substances.
Can Agilent Advanced Therapeutics develop and optimize new synthetic routes?
Yes. Our process chemistry teams specialize in route scouting, impurity mapping, and the design of safe, scalable, and efficient processes that transition smoothly from development into GMP manufacturing.
Do you support lipid, PEG, and linker chemistries for advanced therapeutics?
Absolutely. We manufacture high-purity lipids for mRNA and LNP formulations, PEG derivatives, and a range of ADC linker chemistries, including bifunctional linkers and polymer-based conjugation agents.
How do you manage highly reactive or hazardous chemistry?
Through flow chemistry, engineered safety controls, temperature-controlled reaction systems, and real-time monitoring. These approaches increase safety, yield, and scalability for exothermic or sensitive reactions.
Are your facilities licensed for controlled substances?
Yes. Our Charlottetown site is a licensed controlled-substance manufacturing facility, with secure handling, comprehensive documentation, and compliance with national and international regulations.
style
id
faqs
Browse the latest news on Advanced Therapeutics manufacturing
BIOVECTRA Is Honored with 2025 CDMO Leadership Award
BIOVECTRA, a part of Agilent Technologies Inc., proudly announces it is the recipient of the 2025 Outsourced Pharma CDMO Leadership Award in the category of biologics. The award recognizes BIOVECTRA’s performance in key areas such as quality, reliability, and technical capability.
3/6/2025
Agilent Completes Acquisition of BIOVECTRA
Agilent Technologies announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
9/20/2024
Agilent Investing $725 Million to Expand Nucleic Acid-Based Therapeutics Manufacturing
Agilent Technologies is investing approximately $725 million to double manufacturing capacity of therapeutic nucleic acids in response to rapid growth of the $1 billion market and strong demand for the company’s high-quality active pharmaceutical ingredients (APIs).
1/10/2023
id
news
Innovative sustainability in water, waste, and energy
The Frederick facility integrates sustainable practices, like closed-cell cooling towers and reverse osmosis systems that save over 16 million gallons of water annually. A solar photovoltaic array generates 500 MWh of clean energy to offset utility demand. Waste reduction initiatives include acetonitrile recovery and destruction of dilute organics.
id
sustainability
Explore more ways to connect with us
Have questions or need a quote? Our manufacturing experts are here to help.
Get support from experienced specialists dedicated to your program’s success.
Upcoming events
See where the Agilent Advanced Therapeutics team will be next. Explore our upcoming conferences, tradeshows, and speaking engagements, and connect with us in person.
